Jordan Franklin, PharmD, Edward Pudim III, PharmD, MPH, Thomas C. Pomfret, PharmD, MPH, BCPS, Mckenzie McVeigh, PharmD, MS 1, Eliza Anderson, PharmD 1, Collin Jerard, PharmD, Karen Stevens, PharmD, Caroline Alper, MD, Karen Clements, MPH, ScD, Kimberly Lenz, PharmD, MBA, FAMCP 1
1 Massachusetts Executive Office of Health and Human Services, MassHealth
Our pharmacy team presented the poster, “Evaluating Medication Adherence Rates Of Long-Acting Injectable (LAI) Cabotegravir Versus Daily Oral Therapies For Pre-Exposure Prophylaxis (PrEP) Of Human Immunodeficiency Virus (HIV) In A Medicaid Population,” at the Academy of Managed Care Pharmacy Conference 2026 Annual Meeting. The poster was developed in collaboration with several colleagues from MassHealth.
The poster compared HIV pre-exposure prophylaxis (PrEP) medication adherence and persistence, incidence of HIV seroconversion, and HIV PrEP-related healthcare utilization and costs among Medicaid members receiving LAI cabotegravir. They found that long-acting HIV PrEP therapy was associated with numerically higher adherence rates and significantly increased persistence compared to daily oral options in this Medicaid population, which supports use in alignment with CDC recommendations.